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HYPERGLYCEMIA IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANT (ALLOHSCT)PATIENTS: PREVALANCE AND IMPACT ON OUT-
COMES
Zimmerman, R.L., Labrezio, F.R., Devetten,M.P., Goldner,W. Univer-
sity of Nebraska Medical Center, Omaha, NE
Background: Immunosuppressive medications such as tacroli-
mus, sirolimus, and corticosteroids are known to cause insulin resis-
tance in solid organ transplant patients (pts). Pts receiving alloHSCT
are often on immunosuppressants and develop some degree of
hyperglycemia. Diabetes and hyperglycemia are associated with
complications such as renal disease, cardiovascular disease, an
increase in inflammatory processes, and increased risk of infections.
We reported the prevalence of hyperglycemia in the first 100 days
following alloHSCT as well as average blood sugar values and the
association between blood sugars, length of stay, renal, pulmonary,
and infectious complications.
Methods:Beginning Feb, 2007, blood sugars on all alloHSCTpts
were monitored for 100 days. Inpts were treated with IV or subcuta-
neous insulin as appropriate for a goal blood sugar\140 ng/dl. ADA
guidelines for diagnosing diabetes (two fasting blood sugars of$126
on separate occasions, or one random blood sugar of $200) were
used to diagnose hyperglycemia in the outpatients. Outpts were
referred to Endocrine (in a timely manner) within 2 days and the
diabetic educators who counseled the pts and family on diet, insulin
therapy, and blood sugar monitoring.
Results: 32 pts received alloHSCT during the study period.
Seventeen pts (53%) required treatment for hyperglycemia. Theme-
dian (range) glucose level was 150 (109–189) in pts who received
treatment while those who did not receive hyperglycemia treatment
was 108 (92–132; (p\ 0.001) In pts who received treatment, 24%
had a prior history of diabetesmellitus,82%were on systemic steroids
vs 40%of the non-treatment group (p5 0.01), and 41%were on total
parenteral nutrition vs none in the non-treatment group (p5 0.005).
The treatment group had a higher rate of acute GVHD, 65% vs 27%
in the non-treatment group (p 5 0.03), while 82% developed some
type of infection versus 20% in the non-treatment group (p 5
\0.001). 18% of the treatment group died within 100 days, while
no deaths occurred in the non-treatment group.
Conclusions: AlloHSCT pts that develop hyperglycemia have
higher rates of infection andGVHD. Pts who developed hyperglyce-
mia also had higher rates of steroid and TPN usage, indicating these
are potential risk factors for the development of hyperglycemia and
merit aggressivemonitoring of blood glucose. Further studies should
evaluate if early hyperglycemia recognition and treatment decrease
the incidence of complications.310
INCREASED MUCOSITIS IN PATIENTS RECEIVING TARGETED VS NON-
TARGETED IV BUSULFAN PRIOR TO ALLOGENEIC STEM CELL TRANS-
PLANTATION
Nimmagadda, S., Sweiss, K., Chunduri, S., Beri, R., Peace, D.J.,
Quigley, J., Dobogai, L., Mahmud, N., Rondelli, D. Section Hematolo-
gy/Oncology, University of Illinois At Chicago, Chicago, IL
In this study we retrospectively analyzed the results of allogeneic
hematopoietic stem cell transplantation (HSCT) in 47 patients who
received a conditioning regimen with fludarabine and myeloablative
doses of intravenous (IV) busulfan (BU). Patients were divided in
two groups: the first (n 5 21) received a fixed dose of IV BU at 3.2
mg/kg in a single dose/day x 4 days; the secondgroup (n5 26) received
targeted doses of IV BU (target AUC: 4800 mM*min) in four single
daily injections. Targeted doses of BU were calculated mostly based
on a pre-transplant test dose, or in some patients based on pharmaco-
kinetics studies done after the first dose of BUduring the conditioning
regimen.Themeandaily dose ofBUadministered in the secondgroup
was 3.4 6 0.6 mg/kg. No significant differences between the two
groups were detected analyzing the characteristics of the patients,
such as age, high risk disease, related vs non-related donor, or
CD341 cell dose. Median time to absolute neutrophil count (ANC)
$ 0.5  109/L was 18 days (range: 11–35) in the group that received
non-targeted BU and 15 days (range: 10–22) (p 5 ns) in the group
that received targeted-BU, whereas median time to platelets $ 20 
109/L was 13 days (range: 0–37) and 15 days (range: 0–49) (p 5 ns),
respectively. Post-transplant mucositis was graded according to theWHO criteria and 73% of the patients who received targeted-BU
experienced a grade 3–4mucositis as compared to 35%of the patients
who received a fixed dose of BU. No differences in other extra-hema-
tologic toxicities were observed, and particularly none of the patients
had venous-occlusive disease (VOD). These findings suggest that the
use of targeted-IV BU results, on average, in the administration of
a higher BU dose compared to the standard 3.2 mg/kg and this could
explain the increased rate of severe mucositis after allogeneic HSCT.
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CONDITIONING WITH NON-TARGETED BUSULFAN AND FLUDARABINE
FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION: A STUDY
OF ENGRAFTMENT KINETICS
Nathan, S., Tuncer, H., Maciejewski, J., Venugopal, P., Larson, M.,
Shammo, J., Gregory, S., Fung, H. Rush University Medical Center, Chi-
cago, IL
Introduction: Busulfan/ Fludarabine (BuFlu) combination che-
motherapy is increasingly being used in reduced intensity allogeneic
transplantation. Targeted Bu has been used by some transplant cen-
ters, however, its impact on engraftment kinetics and outcome are
not clear. Here, we report our experience with using a non-targeted
Bu and Flu conditioning regimen for allogeneic stem cell transplan-
tation (AlloSCT).
Methods:Data from 24 consecutive patients (pts), undergoingAl-
loSCT using the BuFlu conditioning regimen [Bu (130mg/m2 IV
daily) and Flu (40mg/m2 daily) x 4 days], treated at our institution,
were collected. Demographics, indication, time to engraftment
(TE), chimeric status at Day (D)100 post-transplant, tolerability
and outcomes were analyzed.
Results: 24 pts (average age 49.95 yrs, range: 26–68yrs) were iden-
tified and analyzed as a retrospective cohort with a follow-up duration
of 208.46 182.5D (Range 21–663D). 12 (50%) pts weremale and 12
(50%) female. 79.2% were Caucasian. 13 (54.2%) pts had$2 comor-
bidities. Indications included de novo or secondary acute myeloge-
nous leukemia, chronic myelogenous leukemia or aplastic anemia,
myelodysplastic syndrome or myeloproliferative disease that failed
prior therapy. 12 (50%) pts (age - 51.836 9.1 yrs) underwentmatched
related donor (MRD) and 12(50%) pts (age – 48.16 12.8 yrs)matched
unrelated donor (MUD) AlloSCT. Time to engraftment was 16.5 6
4.63 D in the MRD pts and 15.54 6 3.3 D in the MUD pts. BuFlu-
related toxicities included mucositis, infections, organ-dysfunction
and graft versus host disease. Chimerism studies were not available
in 5 pts. At D100 post-AlloSCT,11 (57.9%) pts. had complete chime-
rism (CC) with .99% donor cells (DC) of who 7 (63.7%) stayed in
remission (CR), 3 (27.3%) died from transplant related toxicities
(TRT) and 1(9%) from relapse, 5 (26.3%) pts had mixed chimerism
(MC) with .90%\99% DC of who 3 (60%) stayed in CR, 2 (40%)
relapsed with one death and 3 (15.8%) pts had MC with\90% DC
of who 2 had persistent and one relapsed disease. Overall, 13
(52.6%) pts stayed in CR, 4 relapsed irrespective of D100 chimeric
status and 9 (37.5%) died from progressive disease or TRT.
Conclusion:We conclude that reduced intensity transplantation,
with non-targeted dose Busulfan and Fludarabine is well tolerated,
with favorable engraftment kinetics and low relapse rates, compara-
ble to historic controls. Therefore, targeted dose Busulfan may not
affect the outcome of transplant.
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MEDICAL MANAGEMENT OF PNEUMATOSIS INTESTINALIS IN PATIENTS
UNDERGOING ALLOGENEIC BLOOD AND MARROW TRANSPLANTATION
Ahluwalia, M.S.1, Anne, N.2, Smiley, S.L.1, Battiwalla, M.1,
Schiff, M.D.1, Loud, P.A.3, Hahn, T.1, Bullard Dunn, K.M.2,
McCarthy, P.L.1 1Roswell Park Cancer Institute, Buffalo, NY; 2Roswell
Park Cancer Institute, Buffalo, NY; 3Roswell Park Cancer Institute, Buf-
falo, NY
Pneumatosis intestinalis (PI) occurs when gastrointestinal (GI)
wall disruption, increased GI wall permeability or necrosis leads to
GI wall infiltration by gas. It is associated with a spectrum of causal
factors including GI disease in allogeneic Blood and Marrow Trans-
plant (alloBMT) patients (pts). Anaerobic bacteria likely produce gas
which accumulates in the GI wall. Traditionally, PI has been man-
aged with surgical exploration with high morbidity and mortality.
We describe our institutional experience managing alloBMT pts
with PI. From 01/98 to 05/08, 320 pts underwent alloBMT of
